Gavo-cel Continues to Demonstrate Clinical Benefit in Solid Tumors with Additional RECIST Responses in Ovarian Cancer and Mesothelioma October 5, 2022
Long-Term Data from Omidubicel Ph 3 Trial Demonstrates OS and Sustainable Durable Outcomes for Patients with Blood Cancers October 5, 2022
Adjuvant Treatment with Opdivo Demonstrated Statistically Significant Improvement in RFS in Patients with Stage IIB/C Melanoma in the CheckMate-76K Trial September 28, 2022
Results from Ph 2 trial of zevorcabtagene autoleucel Ph 1b/2 study in RRMM patients announced September 28, 2022
Recommended Dose for Planned Registrational Study of NBTXR3 Plus Anti-PD-1 for Patients With mSCCHN Resistant to Prior Immunotherapy Established September 28, 2022
Lumakras® (Sotorasib) + Vectibix® (Panitumumab) Shows Confirmed 30% ORR In Patients With KRAS G12C-Mutated mCRC September 13, 2022
Imfinzi + chemo further improved OS benefit in advanced biliary tract cancer in the TOPAZ-1 Ph 3 trial, reducing the risk of death by 24% in additional follow-up September 13, 2022
Detailed Results from Ph 3 COSMIC-313 Pivotal Trial in Patients with 1L RCC announced September 13, 2022
Dose-Escalation Results from Ph 1 STELLAR-001 Trial of XL092 +/- atezolizumab in Patients with Advanced Solid Tumors announced September 13, 2022
Trodelvy® Significantly Improved OS In Pre-Treated HR+/HER2- Metastatic Breast Cancer Patients In TROPiCS-02 Study September 13, 2022
Adagrasib +/- cetuximab demonstrates promising clinical efficacy and favorable tolerability in heavily pretreated CRC patients with KRASG12C mutation September 13, 2022
Kisqali® Adds One More Year Of Survival Benefit For Broadest Set Of Patients, Including Those With Aggressive HR+/HER2- Advanced Breast Cancer September 13, 2022
Long-term data from the Ph 3 PRIMA study showed Zejula (niraparib) maintaining a sustained and clinically meaningful PFS benefit in 1L ovarian cancer patients September 13, 2022
Lynparza +/- bevacizumab demonstrates clinically meaningful survival benefit in 1L advanced ovarian cancer across PAOLA-1 and SOLO-1 Ph 3 trials September 13, 2022
Camrelizumab + Rivoceranib (Apatinib) Significantly Prolonged OS & PFS vs Sorafenib in Patients with uHCC in a Multinational Ph 3 Trial September 13, 2022
Results From Ph 3 LEAP-002 Trial of KEYTRUDA® + LENVIMA® Versus LENVIMA Monotherapy in Patients With uHCC presented September 13, 2022
Tislelizumab demonstrated efficacy and tolerability in 1L advanced liver cancer in Ph 3 RATIONALE 301 trial September 13, 2022
DS-7300 Continues to Show Promising Durable Response in Patients with Several Types of Advanced Cancer September 13, 2022
Interim clinical data of RLY-4008 from Ph 1/2 clinical trial in patients with FGFR2-altered CCA and multiple other solid tumors announced September 13, 2022
Updated Findings from the Ph 2 SUMMIT Basket Trial of Neratinib for HER2-Mutant, Recurrent/Metastatic Cervical Cancer presented September 13, 2022
Patient-Reported Outcomes with Mirvetuximab vs Chemo in FORWARD I Study Reinforces Differentiated Tolerability Profile September 13, 2022
Rubraca® (Rucaparib) As 1L Maintenance Treatment Improves PFS In Women With Advanced Ovarian Cancer Across Disease Risk Subgroups September 13, 2022
KEYTRUDA + Chemo Showed Sustained OS Benefit vs Chemo Alone in in KEYNOTE-189 and KEYNOTE-407 trials for mNSCLC September 13, 2022
Tagrisso demonstrated 5.5-year mDFS in the adjuvant treatment of patients with EGFR-mutated lung cancer September 13, 2022
